Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 48, 2013
Previous Article Next Article

A new design for nucleolipid-based Ru(iii) complexes as anticancer agents

Author affiliations


In continuation with our studies concerning the synthesis, characterization and biological evaluation of nucleolipidic Ru(III) complexes, a novel design for this family of potential anticancer agents is presented here. As a model compound, a new uridine-based nucleolipid has been prepared, named HoUrRu, following a simple and versatile synthetic procedure, and converted into a Ru(III) salt. Stable formulations of this highly functionalized Ru(III) complex have been obtained by co-aggregation with either the zwitterionic lipid POPC or the cationic DOTAP, which have been subjected to an in-depth microstructural characterization, including DLS, SANS and EPR measurements. The in vitro bioactivity profile of HoUrRu, as a pure compound or in formulation with POPC or DOTAP, reveals high antiproliferative activity against MCF-7 and WiDr human cancer cell lines.

Graphical abstract: A new design for nucleolipid-based Ru(iii) complexes as anticancer agents

Back to tab navigation

Supplementary files

Article information

24 Aug 2013
24 Sep 2013
First published
24 Sep 2013

Dalton Trans., 2013,42, 16697-16708
Article type

A new design for nucleolipid-based Ru(III) complexes as anticancer agents

D. Montesarchio, G. Mangiapia, G. Vitiello, D. Musumeci, C. Irace, R. Santamaria, G. D'Errico and L. Paduano, Dalton Trans., 2013, 42, 16697
DOI: 10.1039/C3DT52320A

Social activity

Search articles by author